Auranofin Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 3 mg
Reference Brands: Ridaura (USA)
Category:
Immune Disorder
AURANOFIN is available in Capsules
and strengths such as 3 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, AURANOFIN is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
AURANOFIN can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Auranofin, marketed under the brand name Ridaura, is an orally administered gold-containing compound classified by the World Health Organization as an antirheumatic agent. It is primarily used in the management of rheumatoid arthritis, a chronic autoimmune condition characterized by joint inflammation, pain, and progressive joint damage.
As one of only two gold compounds still employed in modern medicine, alongside sodium aurothiomalate, auranofin works by modulating the immune system and reducing inflammatory responses. It inhibits certain immune pathways and decreases the activity of inflammatory cells, helping to control joint swelling, tenderness, and stiffness.
Administered orally as a 3 mg capsule, auranofin offers a convenient treatment option for long-term management of rheumatoid arthritis. Regular monitoring is recommended during therapy to detect potential side effects, which may include gastrointestinal discomfort, skin reactions, or hematologic changes. Through its targeted immunomodulatory activity, Ridaura remains a valuable therapeutic option for patients requiring disease-modifying antirheumatic treatment, supporting improved joint function and quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing